Related Experiment Video

Updated: May 21, 2026

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
09:57

Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells

Published on: January 29, 2019

Chemotherapeutic candidate inducing immunological death of human tumor cell lines

Su-Jin Oh1, Chung-Kyu Ryu, Inhak Choi

  • 1Office of Biomedical Professors, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, Korea.

Immune Network
|June 29, 2012
PubMed

Insights

The novel compound EY-6 induces immunological cell death in human cancer cells, including colon, gastric, and myeloma lines. This immuno-chemotherapeutic agent shows potential for targeted cancer treatment.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Tumor cell death induction is a key goal in cancer therapy.
  • Immunological cell death (ICD) offers a promising avenue for targeted cancer treatments.
  • Identifying novel compounds that can trigger ICD is crucial for developing new therapeutics.

Purpose of the Study:

  • To screen the compound EY-6 for its ability to induce immunological death in human tumor cell lines.
  • To investigate the dose-dependent effects of EY-6 on various cancer cell types.
  • To analyze the modulation of CRT expression and cytokine secretion in response to EY-6 treatment.

Main Methods:

  • Screening of EY-6 on human colon carcinoma (HCT15, HCT116), gastric carcinoma (MKN74, SNU668), and myeloma (KMS20, KMS26, KMS34) cell lines.
  • Assessment of cell death induction in a dose-dependent manner.
  • Measurement of Calreticulin (CRT) expression as a marker for immunological death.
  • Analysis of cytokine (IFN-γ, IL-12) secretion from treated tumor cells.

Main Results:

  • EY-6 induced cell death in colon, gastric, and myeloma cell lines in a dose-dependent manner.
  • CRT expression, a marker of immunological death, increased in treated colorectal and gastric cancer cells.
  • EY-6 exhibited complex, cell-line-dependent effects on myeloma cells.
  • Cytokine secretion (IFN-γ, IL-12) increased significantly in most treated cells, with exceptions noted in specific cell lines (HCT116, SNU668, KMS26).

Conclusions:

  • EY-6 demonstrates potential as a novel immuno-chemotherapeutic agent capable of inducing tumor-specific cell death.
  • The compound's differential effects on myeloma cells warrant further investigation.
  • Future in vivo studies are planned to confirm the therapeutic efficacy of EY-6.
Keywords:
CalreticulinHuman tumor cellsImmunological deathIndoledione derivative

More Related Videos

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...